Download PDF Brochure Here

Assisted living centers or the assisted living communities generally serve the people who requires help for their daily activities and some of the healthcare services. The centers or the communities are combination of the independence, companionship, privacy and have security and premises that resembles like homes. The rise in the Alzheimer’s diseases are leading to the growth of the assisted living care, there are approximately 28,9000 assisted living centers owing approximately 1 million licensed beds in the United States. The average number of the licensed beds in an assisted living center is 33.

According to the recent data published in 2019 by Alzheimer's Association states that approximately 5.8 million Americans are suffering with Alzheimer’s and the number is expected to rise approximately up to 14 million by 2050.

The cost incurred in the disease are rising in the region. It was estimated that by 2019 Alzheimer’s and other form of dementias will cost nearly US$ 290 billion and it is also estimated that by 2050 the cost can rise roughly up to US$ 1.1 trillion. For the seniors citizens living with the dementia are provided care of nearly 18.5 billion hours which is fairly valued approximately US$ 234 billion.

Source: TheInsightPartners

Request sample PDF Brochure Here

Wireless brain sensors are devices that help monitoring the temperature, detecting the intracranial pressure, and record brain signaling in the form of brain waves. The essential aim of this wireless brain sensor is of securing the person from emergency situations. The devices are primarily used for patients experiencing conditions such as sleep disorders, traumatic brain injury, dementia, Parkinson’s disease, and other neurological conditions. These devices aid in observing and monitoring the neurological deviations and provide support for improving the cognitive functionalities. Accessibility of these sensors is easy from a remote area through wireless connectivity and be integrated with smart phones, tablets and computers, consequently be monitored intermittently from a homecare environment, making the device more cost-efficient. Brown University based neuroengineers team has developed a fully rechargeable and implantable wireless brain sensor, having the capability of relaying broadband signals at real-time from up to hundred neurons in freely moving subjects.

Key players operating in the global wireless brain sensor market include EMOTIV, Muse, NeuroSky, Neuronetrix Solutions, LLC dba COGNISION, Neuroelectrics, Brain Products GmbH, Hangzhou Zhongheng Electric Co., Ltd., Advanced Brain Monitoring Inc., NeuroTherapeutics, Novo Nordisk A/S and others.

Source: citiusmind & TheInsightpartners

Most of the bleeding disorders are inherited and are not completely curable. However, various treatments are available to control the symptoms. The global bleeding disorder market is expected to be driven by the increasing number of diagnosed patients with bleeding disorders across the globe, awareness about bleeding disorder among global population, and government initiatives in developed countries toward the establishment of wide network of diagnosis and treatment centers for bleeding disorders.

Download PDF Brochure, Click Here

Bleeding disorder is a medical situation described by the despicable working of blood clotting procedure known as coagulation. Body’s coagulation framework can’t shape blood clumps at the site of damage or injury, at cuts made amid surgery, feminine cycle which results in large amounts of blood loss. Different treatment choices are available for bleeding disorders such as, substitution treatments which incorporate replacement of coagulating, iron supplementation and fresh frozen plasma and platelet transfusion.

According to the Hemophilia Federation of America, over 20,000 people are affected with hemophilia and 1% of population is suffering with Von Willebrand Disease (VWD). Asia Pacific is expected to witness exponential growth during the forecast period owing to emerging economies such as India and China. According to UNAIDS, there were an estimated 36.9 million people globally were living with HIV in 2017. Out of 36.9 million 1.8 million people became newly infected with HIV in 2017.

In Feb 2019, Roche to acquire Spark Therapeutics. Spark Therapeutics is a fully integrated, commercial company it is working in genetic diseases, including blindness, hemophilia, lysosomal storage disorders and neurodegenerative diseases.
In Feb 2019, FDA approves Cablivi®, Cablivi® is made by Sanofi. It is First medicine approval in the U.S. specifically for the treatment of a TTP, a rare blood-clotting disorder. Sanofi is a global biopharmaceutical company focused on human health. It will change market dynamics.

Few of the major competitors currently working in the bleeding disorders treatment market are Shire (U.S.), Baxter (U.S), CSL (U.S.), Alnylam Pharmaceuticals, Inc.(U.S), Bayer AG (Germany), Novo Nordisk A/S (Denmark), Pfizer Inc. (U.S.), Xenetic Biosciences, Inc. (U.S), Biogen (U.S.), Bristol-Myers Squibb Company (U.S), Octapharma (Switzerland), Sanofi (France), Amgen, Inc.(U.S), Bioverativ (U.S), Janssen Global Services, LLC (U.S), Cangene Corporation (Canada), and among others.

Source: The insight Partners

Tattoo is defined as the temporary or permanent mark made on body part by inserting pigment or ink under the skin. It is associated with various sentimental and ritual values of people, since ancient times. Now-a-days, the tattoos market is growing at a phenomenal rate, leading to upsurge in the tattoo removal market as well. There are several tattoo removal procedures, which include laser, surgical, creams, and others (intense pulsed light therapy, saline, deep chemical peels, and rejuvi). Among these, laser is the widely preferred method owing to its accuracy in removing tattoos and relatively lesser side effects, while surgical procedure such as dermabrasion & surgical excision is a long healing and painful process. Moreover, tattoo removal creams are also available in the market. Usage of these creams is painless, however, time taking, but they have various side effects depending upon the skin type, and the removal is not precise.

Download PDF Brochure, Click Here

People tend to get rid of their tattoos due to various reasons. Some of these include career purposes, social conditions, personal situations, and more, which has been the key driver for tattoo removal market. Moreover, change in the lifestyle and constantly changing trends has increased the demand for tattoo removal in the market. However, high cost and the various side effects associated with tattoo removal procedures hinder the growth of the tattoo removal market.

The laser procedure of tattoo removal is the most prevalent and attractive segment owing to its effectivity and minimal side effects, while erasing tattoo. The different type of lasers used in the tattoo removal industry include Q-switched ruby laser, Q-Switched Nd-YAG laser, and Q-Switched Alexandrite laser. These are used to remove black as well as colored tattoos in approximate seven or more sessions or visits.

The key players operating in the tattoo removal are Alma Lasers, Asclepion Laser Technologies GmbH, BISON MEDICAL, Cutera, Inc., Cynosure, Inc., Cryomed Aesthetics, Eclipse Lasers Ltd., LUMENIS, Syneron Inc., and Fotona d.o.o.

Other players in the value chain include Advance Medical Systems, Astanza Laser, AYALASERS, Dimyth Beauty Equipment Manufacturer, Light Age Inc., LUTRONIC, Quanta Aesthetic Lasers USA, WONTECH, and Yuwei Laser Technology Co., Ltd.

Request 150 pages PDF Brochure for Study Here

Source:Theinsightpartners

Recognizing the interdisciplinary understanding of medical disorders secondary to dysfunctional sleep highlights the value for considering the integration of neurodiagnostic services.

Neurodiagnostic and sleep technologists alike complete the same specialized training to learn application of EEG, electrocardiogram (ECG), and eye leads for monitoring clinical parameters. Both techs study cardiovascular, respiratory, psychiatric, and neurologic disorders. There is a technical overlap of the electrical parameters required to perform both EEG and polysomnography (PSG), including adjustment and documentation of gain, filters, calibrations, and impedances. Some recording devices on the market even have the capability of recording both EEG and PSG on the same device, which makes such equipment a cost-effective investment for sleep labs that offer both neurodiagnostic and sleep services.

Request PDF Copy Here http://bit.ly/2wyCsfz

The process for completing credentialing to perform both EEG and PSG is comparable, with some techs electing to complete credentialing in both. Techs with dual credentials provide a staffing bridge between the neurodiagnostic and sleep centers. EEG techs who work days can also be trained to perform daytime multiple sleep latency tests and maintenance of wakefulness tests, which are in the domain of the sleep center. Also, since the same techs with expertise in neurodiagnostic and sleep studies are observing the EEG for symptoms of SDB, it follows that more studies will be referred to the sleep center for testing.

Market Trends

Neuroimaging advances including magnetic resonance imaging (MRI), single-photon emission computed tomography (SPECT), EEG, and magnetoencephalography (MEG) improve diagnosis of neurologic disorders. New biomarkers and imaging protocols contribute to earlier diagnosis and monitoring of disease. Neuroinformatics provide multidimensional databases and software systems that store and analyze data ranging from genetic to behavioral scopes.

Key clinical directions add to the benefits of sleep center diversification. The aging market impacts the demand for more research and sustainable treatment options of neurodegenerative disorders, Parkinson’s disease, and other movement disorders. Novel stimulation devices are available for the treatment of asthma, migraine, and epilepsy. There is a demand to use diagnostics to change the treatment landscape of anxiety, depression, and attention deficit hyperactivity disorder.

Leading companies operating in this research are GE Healthcare, Koninklijke Philips N.V., Siemens Healthineers, Hitachi, Ltd, Canon, Inc., Natus Medical Incorporated, F. Hoffmann-La Roche Ag, Advanced Brain Monitoring, Inc, Lifelines Neuro, Mitsar Co. etc.

Neurodiagnostics and assessment of sleep disorders both impact the management of psychiatric disorders, mood and anxiety disorders, as well as neuromuscular disorders.

Source: sleepreviewmag

Increasing prevalence of cancer and other genetic disorders, growing preference for personalized medicine, Increase in R&D expenditure and growth of biotechnology and pharmaceutical industries, are some of the factors propelling the growth of the genome editing market. However, high cost of genomic equipment may impede the market growth.

Get PDF Brochure Here http://bit.ly/3bQ3OxT

For instance, the first-ever human trials of CRISPR focused on treating a various cancers in China and the first human trials for CRISPR tech in the US set to focus on disease such as sickle cell. Progress in availability of computational tools and wet-lab genome editing (GE) technologies have greatly expanded the capability for the complex requirements of system-level investigation of microbes. Microbial gene editing tools such as targetrons, zinc finger nucleases (ZFNs), meganucleases (MNs), (CRISPR)-associated nuclease Cas9 and transcription activator-like effector nucleases (TALENs), and, creates huge opportunity for the gene editing in the forecast period. All these tools can achieve accurate and precise genetic modifications by inducing targeted DNA double strand breaks.

There are approximately 2,700 clinical trials using gene therapies under way or approved around the world. Furthermore increasing number of skilled labors will create opportunity for development of new tools in future which will bring significant growth in the revenue of microbial gene editing services market in the forecast period.

Key service provider present in the global microbial gene editing services market are GenScript USA, Horizon Discovery Group plc., Integrated DNA Technologies Inc., Lonza Group Ltd, Merck & Co., New England Biolabs Inc., Origene Technologies Inc., Sangamo Biosciences, Thermo Fisher Scientific, Transposagen Biopharmaceuticals.

Source: The Insight Partners

The organ-on-chip market consists of sales of organs-on-chips by entities (organizations, sole traders and partnerships) that manufacture organs-on-chips used for drug development, toxicity testing, and personalized medicine research. Organs-on-chips (OOCs) are small plastic devices with biocompatible microfluidic chambers containing multiple live human cells in a 3D culture that simulate key physiological functions of body organs. Organs-on-chips that mimic the organ level physiology of humans are a promising alternative to animal models.

Get sample PDF brochure @ http://bit.ly/2vrii6K

Adoption Of OOC Technology By Major Pharmaceutical Companies – OOCs are now being explored worldwide as tools for developing disease models and accurately predicting drug efficacies and toxicities. Many companies and universities have been continuously looking for new and better models for drug development. The advantages of OOCs over cell culture, animal models, and human clinical trials have captured the attention of the medical and pharmaceutical communities focusing on developing targeted therapies.

Surge in Applications of Organ-on-chip Devices in the Healthcare Sector

Surge in demand for organ-on-chip devices in the healthcare industry is expected to boost the growth of the global market. Organ-on-chip devices are applicable in real-time imaging, in-vitro analysis of biochemical, and genetic & metabolic activities of living cells in a functional tissue, which significantly fuel their adoption.

Increase in Demand for Organ-on-chip in Drug Screening

Drug screening is a cost-effective method used for rapidly reviewing samples. Scientists and researchers use organ-on-chip culture devices to monitor the effects of drugs in the body. Furthermore, drug toxicity or drug effectiveness in various organs of the body is checked using this technique, which boosts the market growth.

Rise in Demand for Lung- & Kidney-based Organ Culture Devices

Shortage of donor lungs for transplantation has led to significant number of patient deaths. Thus, rise in demand to develop laboratory-engineered, functional organs is anticipated to supplement the growth of the market. Recellularized solid organs can perform organ-specific functions for short span of time, which indicates the potential for clinical use of engineered solid organs in the future.

Source: The Insight Partners

However, by promoting efficiency in the healthcare supply chain, hospitals and physician practices can create substantial cost-reducing opportunities across their organization.

Here is a look at what goes into healthcare supply chain management and how healthcare organizations can overcome major challenges to further reduce spending.

Download PDF Brochure of Study @ http://bit.ly/2ONMBvd

What is healthcare supply chain management?

Take a moment to think about what providers use every day to treat patients. Providers use a myriad of items, such as syringes, prescriptions drugs, gloves, pens, papers, and computers. Employees involved in healthcare supply chain management are responsible for stocking organizations with the products providers need and managing inventory.
The healthcare supply chain starts at the medical product manufacturer where items are produced and sent to a distribution center. Depending on the type of product, hospitals can either purchase inventory directly through the manufacturer or distributor, or the transaction can be conducted through a group purchasing organization, which establishes a purchasing contract with the manufacturer on behalf of the hospital.

Why is healthcare supply chain management so complex?

Healthcare supply chain management is unique because each stakeholder has their own interests to protect. Different stages in the supply chain flow may be focused on their own goal. Providers may want to use a specific product because they were trained with it, whereas hospital executives aim to purchase the most affordable quality items.

Since supply chain goals are not always aligned within an organization, the healthcare supply chain management process can be inefficient and fragmented. Healthcare organizations must take into account numerous requests and viewpoints to settle on specific product budgets.

Patients also have a voice in the healthcare supply chain management process. Healthcare organizations may be able to regularly order the correct sizes of gloves and keep them stocked, but some patients may need more customized medical products, such as latex-free options, depending on their health status.

The healthcare supply chain management market, based on the component is segmented into hardware and software. The hardware segment is further classified into, systems, barcodes, RFID and others and the software segment is further classified into, supplier management software, transportation software, procurement software and others software. Based on the delivery model, the healthcare supply chain management market is segmented as, on premise, cloud based and web based.

Some of the key players operating in this market place include SAP AG Group, Oracle Corporation, McKesson Corporation, Providence Health & Services, Geisinger Health System, AmerisourceBergen, Intermountain Healthcare, Advocate Health Care and others.

Source: revcycleintelligence

Ayurveda is a system of medicine that has its origination roots in the Indian subcontinent. It uses natural healing practices to cure clinical conditions such as sinusitis, cough, depression, and insomnia. Ayurveda therapies have been integrated in general wellness and in some cases in medical use worldwide. In addition, ayurvedic ingredients are extensively used in personal care products and health supplements along with drugs.

Get sample PDF Brochure of study @ http://bit.ly/2wb5GBf

The growth of the global ayurvedic market is driven by increase in awareness of adverse effects of allopathy among consumers. In addition, other factors that drive the market growth are easy availability, affordability, and increase in awareness of the benefits of ayurvedic products. Moreover, expanding medical tourism across the globe is expected to propel the market growth. However, factors which hamper the growth of this market include lack of standardization of procedures to manufacture ayurvedic products and inconsistent supply of raw materials. Conversely, rise in awareness about ayurvedic natural ingredients in health and personal care products in the developed countries such as the U.S., Canada, Australia, Singapore, and Japan is expected to offer growth opportunity for the market in the near future.

The global ayurvedic market is categorized on the basis of product, distribution channel, and region. Based on product, the market is categorized into healthcare products, personal care products, skin care, hair care, oral care, and drugs. By distribution channel, it is classified into supermarkets, pharmacies, departmental stores, beauty spa/salon, internet retailing and, specialty stores. Regionally, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, UK, France, Spain, Italy, and rest of Europe), Asia-Pacific (Japan, China, Singapore, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).

The key players operating in the global ayurvedic market are Emami Limited, Charak Pharma Pvt. Ltd., Vicco Laboratories, Patanjali Ayurved Limited, Leverayush, Dabur India Limited, SHREE BAIDYANATH AYURVED BHAWAN PVT. LTD., and the Himalaya Drug Company.

Source: The Insight Partners

Drug discovery is the preliminary step in the process of a novel drug identification and its therapeutic target. Artificial intelligence (AI) is commonly used in the healthcare industry for drug discovery. Artificial intelligence technology has the ability to recognize drug targets, and play a significant role in drug design, discovery, identification and screening of molecules instantly and effectively. Drug discovery or new drug target are being estimated based on potency, bioavailability, efficacy, and toxicity.

Download PDF Brochure http://bit.ly/2tBav5F

In the clinical setting, AI works with known parameters, typically running through a classification process based on experiences of what works and what doesn’t for different types of patients. The potential of AI here is significant, and the early successes are truly exciting.

The opportunity is equally compelling in drug discovery, particularly in areas of high unmet need such as rare and hard-to-treat cancers and neurodegenerative conditions. Artificial intelligence can ingest and reason over information from the scientific literature and databases, as well as patient-level data, to identify potential approaches to treat diseases by proposing a drug target, designing a molecule, and defining patients in which to test that molecule to drive greater clinical success.

But the questions being asked of artificial intelligence in this sphere are fundamentally different than they are in clinical applications. AI is in uncharted territory here, searching for the novel, not the known. In any setting, AI requires training with positive — and ideally some negative — examples. This is a particular challenge in predicting new targets for glioblastoma, Parkinson’s, and other conditions for which no treatment has yet been shown to reverse the disease course.

The potential of AI in drug discovery

The pharmaceutical industry is facing a crisis is R&D. About 50% of late-stage clinical trials fail due to ineffective drug targets, resulting in only 15% of drugs advancing from Phase 2 to approval. And researchers tend to coalesce around the same disease areas and targets.

Artificial intelligence can help expand the drug discovery universe by making predictions in more novel areas of biology and chemistry. By extracting text from scientific papers, AI can help identify relevant information faster and make links between biomedical entities, such as medicines and proteins, often with relatively little information.

In amyotrophic lateral sclerosis (ALS), for example, 50 clinical trials in the last two decades have failed to show any positive results, leaving only two approved drugs on the market that have shown only modest benefits to patients. This is an area crying out for new approaches.

Followings are the companies operating in this research:

• Atomwise, Inc.
• Insilico Medicine
• BIOAGE
• Numerate
• NuMedii, Inc.
• Envisagenics
• Cloud Pharmaceuticals, Inc.
• BenevolentAI
• twoXAR, Incorporated
• Exscientia

Source: statnews & theinsightpartners